{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:23:06Z","timestamp":1789770186504,"version":"4.0.1"},"reference-count":110,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.atherosclerosis.2007.01.023","type":"journal-article","created":{"date-parts":[[2007,3,8]],"date-time":"2007-03-08T21:45:00Z","timestamp":1173390300000},"page":"823-834","source":"Crossref","is-referenced-by-count":51,"title":["Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials"],"prefix":"10.1016","volume":"196","author":[{"given":"Doris T.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley B.","family":"Irish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursharan K.","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib1","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib2","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4065\/80.10.1270","article-title":"Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study","volume":"80","author":"Foley","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/ndt\/gfh813","article-title":"Chronic kidney disease as cause of cardiovascular morbidity and mortality","volume":"20","author":"Vanholder","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(00)02456-9","article-title":"Premature cardiovascular disease in chronic renal failure","volume":"356","author":"Baigent","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/ndt\/15.2.218","article-title":"Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure","volume":"15","author":"Schwarz","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/hy1001.096358","article-title":"Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease","volume":"38","author":"Blacher","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib8","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1046\/j.1523-1755.2003.00932.x","article-title":"Aortic pulse wave velocity index and mortality in end-stage renal disease","volume":"63","author":"Blacher","year":"2003","journal-title":"Kidney Int"},{"issue":"Suppl. 4","key":"10.1016\/j.atherosclerosis.2007.01.023_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ndt\/13.suppl_4.12","article-title":"Arterial function in renal failure","volume":"13","author":"London","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib10","doi-asserted-by":"crossref","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib11","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1046\/j.1523-1755.63.s84.3.x","article-title":"Dialysis modalities and dyslipidemia","author":"Attman","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.metabol.2004.05.001","article-title":"Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome","volume":"53","author":"Batista","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1081\/JDI-100100852","article-title":"Lipoprotein profiles at different stages of chronic renal insufficiency","volume":"22","author":"Kimak","year":"2000","journal-title":"Ren Fail"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.mcna.2004.11.002","article-title":"Dyslipidemias in patients who have chronic kidney disease","volume":"89","author":"Farbakhsh","year":"2005","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0272-6386(00)70255-1","article-title":"Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation","volume":"35","author":"Deighan","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib16","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1046\/j.1523-1755.63.s84.34.x","article-title":"Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms","author":"Prinsen","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib17","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/ki.1996.192","article-title":"Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma","volume":"49","author":"Cheung","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib18","first-page":"S90","article-title":"Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation","volume":"62","author":"Nishizawa","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib19","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/ki.1992.411","article-title":"Severe defect in clearing postprandial chylomicron remnants in dialysis patients","volume":"42","author":"Weintraub","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib20","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1523-1755.2005.00166.x","article-title":"Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure","volume":"67","author":"Kim","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib21","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1046\/j.1523-1755.2001.00734.x","article-title":"Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure","volume":"59","author":"Vaziri","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib22","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1681\/ASN.2005010106","article-title":"Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults","volume":"16","author":"Kurella","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/j.1523-1755.2004.00466.x","article-title":"A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis","volume":"65","author":"Prinsen","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1523-1755.1998.00831.x","article-title":"Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis","volume":"53","author":"de Sain-van der Velden","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJM199008303230905","article-title":"Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome","volume":"323","author":"Joven","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib26","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1046\/j.1523-1755.1999.07105.x","article-title":"New insights into lipid metabolism in the nephrotic syndrome","volume":"71","author":"Kaysen","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib27","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1046\/j.1523-1755.2003.00941.x","article-title":"Molecular mechanisms of lipid disorders in nephrotic syndrome","volume":"63","author":"Vaziri","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0272-6386(12)80994-2","article-title":"Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment","volume":"23","author":"Wheeler","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib29","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/ki.1995.500","article-title":"Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis","volume":"48","author":"Vaziri","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/ki.1996.388","article-title":"Down-regulation of hepatic LDL receptor expression in experimental nephrosis","volume":"50","author":"Vaziri","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1523-1755.2004.00724.x","article-title":"Up-regulation of hepatic Acyl CoA: diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome","volume":"66","author":"Vaziri","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib32","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1993.292","article-title":"The increased risk of coronary heart disease associated with nephrotic syndrome","volume":"44","author":"Ordonez","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00467-004-1460-x","article-title":"The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome","volume":"19","author":"Lechner","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1525-139X.2006.00117.x","article-title":"Lipid abnormalities associated with end-stage renal disease","volume":"19","author":"Liu","year":"2006","journal-title":"Semin Dialysis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib35","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1081\/JDI-120013966","article-title":"Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients","volume":"24","author":"Fytili","year":"2002","journal-title":"Ren Fail"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib36","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1046\/j.1523-1755.1999.00375.x","article-title":"Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis","volume":"55","author":"Attman","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/pgmj.2004.025601","article-title":"Pathophysiology of dyslipidaemia in the metabolic syndrome","volume":"81","author":"Kolovou","year":"2005","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib38","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/089686080202200209","article-title":"Alterations in lipoprotein composition in peritoneal dialysis patients","volume":"22","author":"Moberly","year":"2002","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib39","first-page":"96","article-title":"Lipid metabolic abnormalities after renal transplantation under cyclosporine and prednisone immunosuppression","volume":"24","author":"Castelao","year":"1992","journal-title":"Transplant Proc"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1399-0012.2004.00160.x","article-title":"A long-term study on hyperlipidemia in stable renal transplant recipients","volume":"18","author":"Tse","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib41","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1053\/ajkd.1998.v32.pm9820472","article-title":"Hyperlipidemia in patients with chronic renal disease","volume":"32","author":"Kasiske","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1081\/JDI-120004095","article-title":"Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients","volume":"24","author":"Kimak","year":"2002","journal-title":"Ren Fail"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000189549","article-title":"Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation","volume":"75","author":"Brown","year":"1997","journal-title":"Nephron"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1399-0012.1998.tb01082.x","article-title":"Lipoprotein abnormalities in long-term stable liver and renal transplanted patients A comparative study","volume":"12","author":"Fernandez-Miranda","year":"1998","journal-title":"Clin Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib45","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1046\/j.1523-1755.1999.07162.x","article-title":"Immunosuppression enhances atherogenicity of lipid profile after transplantation","volume":"71","author":"Quaschning","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib46","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/01.ASN.0000071515.27754.67","article-title":"Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus","volume":"14","author":"Artz","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/01.TP.0000074310.40484.94","article-title":"Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis","volume":"76","author":"Chueh","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib48","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","article-title":"Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients","volume":"43","author":"Morrisett","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00007890-199702150-00001","article-title":"Hyperlipidemia in solid organ transplantation","volume":"63","author":"Kobashigawa","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib50","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/ki.1996.346","article-title":"ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease","volume":"50","author":"Berg","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ajhp\/61.6.565","article-title":"Drug-related dyslipidemia after renal transplantation","volume":"61","author":"Mathis","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib52","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/S0041-1345(03)00233-1","article-title":"Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients","volume":"35","author":"Morrisett","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib53","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/00007890-200110150-00011","article-title":"Effect of sirolimus on the metabolism of apo","volume":"72","author":"Hoogeveen","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib54","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0041-1345(00)01884-4","article-title":"Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia","volume":"32","author":"Tur","year":"2000","journal-title":"Transplant Proc"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib55","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000182627","article-title":"Mortality risk factors in patients treated by chronic hemodialysis Report of the Diaphane collaborative study","volume":"31","author":"Degoulet","year":"1982","journal-title":"Nephron"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib56","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1046\/j.1523-1755.2002.00324.x","article-title":"Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients","volume":"61","author":"Iseki","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.291.4.451","article-title":"Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition","volume":"291","author":"Liu","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib58","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1053\/ajkd.2001.27393","article-title":"Atherogenic lipoproteins in end-stage renal disease","volume":"38","author":"Shoji","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib59","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.ajkd.2005.07.048","article-title":"Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD","volume":"46","author":"Preston","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib60","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1093\/ndt\/12.12.2597","article-title":"Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study","volume":"12","author":"Jungers","year":"1997","journal-title":"Nephrol Dialysis Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib61","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib62","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib63","first-page":"601","article-title":"Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses","volume":"16","author":"Briel","year":"2005","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib65","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib66","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib67","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib68","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","article-title":"Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency","volume":"66","author":"Tonelli","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib69","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib70","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib71","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ahj.2005.06.017","article-title":"Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function","volume":"151","author":"Isbel","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.ajkd.2005.11.018","article-title":"The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD","volume":"47","author":"Landray","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib73","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib74","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2005.05.014","article-title":"Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study","volume":"46","author":"Jardine","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib75","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib76","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/ndt\/gfh735","article-title":"Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation","volume":"20","author":"Holdaas","year":"2005","journal-title":"Nephrol Dialysis Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib77","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib78","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1523-1755.2001.00487.x","article-title":"Effect of lipid reduction on the progression of renal disease: a meta-analysis","volume":"59","author":"Fried","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib79","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","article-title":"Statins for improving renal outcomes: a meta-analysis","volume":"17","author":"Sandhu","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib80","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","article-title":"The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study","volume":"57","author":"Athyros","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib81","first-page":"A316","article-title":"Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: the Treating to New Targets (TNT) Study","volume":"47","author":"Shepherd","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 3","key":"10.1016\/j.atherosclerosis.2007.01.023_bib82","first-page":"iii67","article-title":"The effects of hyperlipidaemia on graft and patient outcome in renal transplantation","volume":"19","author":"Del","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib83","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1523-1755.2004.00919.x","article-title":"Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial","volume":"66","author":"Fellstrom","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib84","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.tp.0000168941.19689.cf","article-title":"Impact of statin treatment on 1-year functional and histologic renal allograft outcome","volume":"80","author":"Masterson","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib85","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib86","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.ajkd.2005.08.012","article-title":"The effect of cholesterol reduction with cholestyramine on renal function","volume":"46","author":"Kshirsagar","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib87","doi-asserted-by":"crossref","first-page":"24F","DOI":"10.1016\/j.amjcard.2005.06.009","article-title":"Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol","volume":"96","author":"Liao","year":"2005","journal-title":"Am J Cardiol"},{"issue":"Suppl. 7","key":"10.1016\/j.atherosclerosis.2007.01.023_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib89","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1592\/phco.2005.25.7.918","article-title":"Retrospective analysis of hyperlipidemia management in a transplant population","volume":"25","author":"Schonder","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib90","first-page":"381","volume":"173","author":"De","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2005.10.001","article-title":"The evolution of European guidelines: changing the management of cholesterol levels","volume":"185","author":"Erhardt","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib92","doi-asserted-by":"crossref","unstructured":"European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrol Dial Transplant, 2002;17(Suppl. 4):26\u20138.","DOI":"10.1093\/ndt\/17.suppl_4.3"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib93","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.hlc.2005.10.010","article-title":"National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management\u20142005","volume":"14","author":"Tonkin","year":"2005","journal-title":"Heart Lung Circ"},{"issue":"Suppl. 5","key":"10.1016\/j.atherosclerosis.2007.01.023_bib94","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1111\/j.1440-1797.2005.00507.x","article-title":"Cardiovascular risk factors","volume":"10","author":"Walker","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib95","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","author":"Baigent","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib96","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1468-6708-6-9","article-title":"Effect of rosuvastatin on outcomes in chronic haemodialysis patients\u2014design and rationale of the AURORA study","volume":"6","author":"Fellstrom","year":"2005","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib97","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.amjcard.2005.12.015","article-title":"An assessment of statin safety by nephrologists","volume":"97","author":"Kasiske","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib98","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.amjcard.2005.12.007","article-title":"Statin safety and drug interactions: clinical implications","volume":"97","author":"Bottorff","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib99","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/ndt\/15.12.1993","article-title":"Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol","volume":"15","author":"Broeders","year":"2000","journal-title":"Dial Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib100","first-page":"39","article-title":"Deterioration in renal function associated with fibrate therapy","volume":"55","author":"Lipscombe","year":"2001","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib101","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib102","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib103","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1600-6143.2006.01263.x","article-title":"A retrospective analysis of ezetimibe treatment in renal transplant recipients","volume":"6","author":"Buchanan","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0828-282X(06)70253-7","article-title":"Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"22","author":"Simard","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib105","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders","volume":"341","author":"Knopp","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib106","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1517\/14656566.5.6.1385","article-title":"Extended-release niacin for modifying the lipoprotein profile","volume":"5","author":"Guyton","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib107","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1753-4887.2006.tb00219.x","article-title":"The role of dietary supplementation with plant sterols and stanols in the prevention of cardiovascular disease","volume":"64","author":"Devaraj","year":"2006","journal-title":"Nutr Rev"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.amjcard.2005.12.022","article-title":"Dietary omega-3 fatty acid intake and cardiovascular risk","volume":"98","author":"Psota","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib109","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjcard.2005.12.024","article-title":"Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids","volume":"98","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.01.023_bib110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.amjcard.2005.12.026","article-title":"Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids","volume":"98","author":"Robinson","year":"2006","journal-title":"Am J Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007000676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007000676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T17:30:22Z","timestamp":1736875822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915007000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0021915007000676"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.01.023","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}